Understanding Lupus Anticoagulant (DRVVT) LA 1 Screen: Normal vs Optimal Ranges

?What is Lupus Anticoagulant (DRVVT) LA 1 Screen?

The lupus anticoagulant (LA) screen using the dilute Russell viper venom time (DRVVT) method is a specialized coagulation test that detects antibodies against phospholipids in the blood. A prolonged result on the screening phase may suggest the presence of lupus anticoagulant, an antiphospholipid antibody associated with increased thrombotic risk. This test is often the first step in identifying antiphospholipid syndrome (APS), though results must be confirmed with additional testing.

!Why It Matters

Lupus anticoagulant may be associated with an increased risk of blood clots (venous and arterial thrombosis) and recurrent pregnancy loss. Detection of LA can guide clinical decision-making regarding anticoagulation therapy and monitoring, particularly in patients with a history of thrombosis, recurrent miscarriages, or autoimmune conditions. A single positive screening result requires confirmation and clinical correlation before diagnosis.

Reference Ranges

Lab normal ranges may vary between laboratories. Optimal and longevity targets are based on research literature and should be interpreted with your physician.

Symptoms of Imbalance

• Unexplained blood clots (deep vein thrombosis or pulmonary embolism)
• Recurrent pregnancy loss or miscarriage
• Prolonged activated partial thromboplastin time (aPTT)
• History of stroke or transient ischemic attack at young age
• Livedo reticularis or other skin manifestations of autoimmune disease

How to Improve Your Levels

• 1If positive, consult with a hematologist or rheumatologist to confirm diagnosis and assess thrombotic risk
• 2Maintain adequate hydration to support healthy circulation
• 3Avoid prolonged immobilization; engage in regular moderate physical activity as advised by your healthcare provider
• 4Follow anticoagulation therapy if prescribed, with regular INR monitoring
• 5Manage underlying autoimmune conditions through appropriate medical treatment
• 6Avoid smoking and estrogen-containing medications when possible, as these may increase thrombotic risk

When to Test

Testing is indicated in patients with unexplained thrombosis, recurrent pregnancy loss, prolonged aPTT on routine screening, personal or family history of thrombotic events, or suspected antiphospholipid syndrome. Repeat testing is typically performed 12 weeks or more after an initial positive result to confirm persistent positivity.

Related Biomarkers